COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,225 Articles (22,733 medRxiv, 8,492 bioRxiv)

Most recent first Previous |  Page 2397: Articles 23961-23970  | Next

The Impact of COVID-19 on Medical Practice: A Nationwide Survey of Dermatologists and Healthcare Providers
Shanshal, M., Ahmed, H. S., Asfoor, H., Salih, R. I., Ali, S. A., Aldabouni, Y. k.
10.1101/2020.07.26.20156380 — Posted: 2020-08-04
Therapeutic effectiveness of interferon alpha 2b treatment for COVID-19 patient recovery
Pereda, R., Gonzalez, D., Rivero, H. B., Rivero, J. C., Perez, a., Lopez, L. d. R., Mezquia, N., Venegas, R., Betancourt, J. R., Dominguez, R. E.
10.1101/2020.07.28.20157974 — Posted: 2020-08-04
Interim Results of a Phase II/III Multicenter Randomized Clinical Trial of AVIFAVIR in Hospitalized Patients with COVID-19
Ivashchenko, A. A., Dmitriev, K. A., Vostokova, N. V., Azarova, V. N., Blinow, A. A., Egorova, A. N., Gordeev, I. G., Ilin, A. P., Karapetian, R. N., Kravchenko, D. V., Lomakin, N. V., Merkulova, E. A., Papazova, N. A., Pavlikova, E. P., Savchuk, N. P., Simakina, E. N., Sitdekov, T. A., Smolyarchuk, E. A., Tikhomolova, E. G., Yakubova, E. V., Ivachtchenko, A. V.
10.1101/2020.07.26.20154724 — Posted: 2020-08-04
Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial
kamran, s. m., Mirza, Z. e. H., Naseem, A., Saeed, F., Azam, R., Ullah, N., Ahmad, W., Saleem, S.
10.1101/2020.07.30.20165365 — Posted: 2020-08-04 Discussion: Onsite
Similarity between mutation spectra in hypermutated genomes of rubella virus and in SARS-CoV-2 genomes accumulated during the COVID-19 pandemic
Gordenin, D. A., Klimczak, L. J., Randall, T. A., Saini, N., Li, J.-L.
10.1101/2020.08.03.234005 — Posted: 2020-08-03 Discussion: Onsite
De novo design of picomolar SARS-CoV-2 miniprotein inhibitors
Baker, D., Cao, L., Goreshnik, I., Coventry, B., Case, J. B., Miller, L., Kozodoy, L., Chen, R. E., Carter, L., Walls, A., Park, Y.-J., Stewart, L., Diamond, M., Veesler, D.
10.1101/2020.08.03.234914 — Posted: 2020-08-03 Discussion: Onsite
PAN-INDIA 1000 SARS-CoV-2 RNA Genome Sequencing Reveals Important Insights into the Outbreak
Maitra, A., Raghav, S., Dalal, A., Ali, F., Paynter, V. M., Paul, D., Biswas, N. K., Ghosh, A., Jani, K., Chinnaswamy, S., Pati, S., Sahu, A., Mitra, D., Bhat, M. K., Mayor, S., Sarin, A., The PAN-INDIA 1000 SARS-CoV-2 RNA Genome Sequencing Consortium, , Shouche, Y. S., Seshasayee, A. S. N., Palakodeti, D., Bashyam, M. D., PARIDA, A., Das, S.
10.1101/2020.08.03.233718 — Posted: 2020-08-03
Structure-Based Design of a Cyclic Peptide Inhibitor of the SARS-CoV-2 Main Protease
Kreutzer, A. G., Krumberger, M., Parrocha, C. M. T., Morris, M. A., Guaglianone, G., Nowick, J. S.
10.1101/2020.08.03.234872 — Posted: 2020-08-03
De novo design of ACE2 protein decoys to neutralize SARS-CoV-2
Linsky, T. W., Vergara, R., Codina, N., Nelson, J. W., Walker, M. J., Su, W., Hsiang, T.-Y., Esser-Nobis, K., Yu, K., Hou, Y. J., Priya, T., Mitsumoto, M., Pong, A., Lau, U. Y., Mason, M. L., Chen, J., Chen, A., Berrocal, T., Peng, H., Clairmont, N. S., Castellanos, J., Lin, Y.-R., Josephson-Day, A., Baric, R. S., Walkey, C. D., Swanson, R., Blancas-Mejia, L. M., Gale, M., Yen, H.-L., Silva, D.-A.
10.1101/2020.08.03.231340 — Posted: 2020-08-03
Structure of SARS-CoV-2 2'-O-methyltransferase heterodimer with RNA Cap analog and sulfates bound reveals new strategies for structure-based inhibitor design
Rosas-Lemus, M., Minasov, G., Shuvalova, L., Inniss, N., Kiryukhina, O., Brunzelle, J., Satchell, K. J.
10.1101/2020.08.03.234716 — Posted: 2020-08-03

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).